Enovis Corporation introduced the one-tray AltiVate Reverse Glenoid System, which expands the glenoid implant offering of the market-leading AltiVate Reverse to include modular, augmented baseplates. Based on the Company's central screw fixation design with a minimum of 10 years of clinical follow-up1, the AltiVate reverse arthroplasty System received FDA 510(k) clearance in May 2024 for use in reverse shoulder arthroplasty, including revisions, making it an important addition to Enovis' AltiVate products. The AltiVate reverse Glenoid System offers a modular baseplate with neutral and 15deg wedge options, as well as multiple central compression screw lengths and diameters.

The baseplate boss was designed to be more bone-sparing than any other currently available baseplate with a comparable central through-screw design to minimize the volume of bone removed and preserve the glenoid vault. It also adds four new glenospheres to the already robust RSP offering, giving surgeons a comprehensive selection to optimize the biomechanical needs of each individual patient and maximize implant longevity. Leverse shoulder arthroplasty represents over 60% of the more than 200,000 shoulder replacements performed annually in the United States.

In a reverse shoulder replacement, the position of the ball and socket are switched. Developed in the 1980s in Europe and approved by the FDA in 2003, indications for this procedure continue to expand, increasing the demand for implants that can be used in a variety of patients. The first surgery using AltiVate Reverse Glenoid was conducted by Dr. Mark Frankle at Tampa General Hospital on July 8. Dr. Frankle is an international leader in shoulder surgery and has been performing reverse shoulder replacements for over two decades.